Search

Your search keyword '"Hsu, Ma"' showing total 312 results

Search Constraints

Start Over You searched for: Author "Hsu, Ma" Remove constraint Author: "Hsu, Ma"
312 results on '"Hsu, Ma"'

Search Results

201. Foreword

202. Title Page

204. Protein, amino acid, and caloric intakes of selected pregnant women

206. The immunomodulator decoy receptor 3 improves locomotor functional recovery after spinal cord injury

208. Superoxide anion radical, lipid peroxides and antioxidant status in the blood of patients with breast cancer.

209. TBK1 and IKKε protect target cells from IFNγ-mediated T cell killing via an inflammatory apoptotic mechanism.

211. Salvage therapy expands highly cytotoxic and metabolically fit resilient CD8 + T cells via ME1 up-regulation.

212. A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma.

214. Cancer-targeted photoimmunotherapy induces antitumor immunity and can be augmented by anti-PD-1 therapy for durable anticancer responses in an immunologically active murine tumor model.

216. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.

219. Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study.

220. Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib.

221. Development and Content Validation of Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD) in Adolescents and Adults with Moderate-to-Severe AD.

222. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.

223. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.

224. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.

225. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.

226. Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States.

227. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.

229. Content validity and psychometric evaluation of Functional Assessment of Chronic Illness Therapy-Fatigue in patients with psoriatic arthritis.

230. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.

231. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.

232. Patient Preferences Associated with Therapies for Psoriatic Arthritis: A Conjoint Analysis.

233. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.

234. The impact of multimorbidity on quality of life among midlife women: findings from a U.S. nationally representative survey.

235. Predictors of functional improvement in employed adults with major depressive disorder treated with desvenlafaxine.

236. Improvements in quality of life with desvenlafaxine 50mg/d vs placebo in employed adults with major depressive disorder.

237. Impact of physician specialty on classification of physician-perceived patient severity for patients with osteoarthritis.

238. Application of Resource Utilization in Dementia (RUD) instrument in a global setting.

239. Other paradigms: health-related quality of life as a measure in cancer treatment: its importance and relevance.

240. Psychometric validation of the cancer therapy satisfaction questionnaire.

241. The orexin-1 antagonist SB-334867 blocks antipsychotic treatment emergent catalepsy: implications for the treatment of extrapyramidal symptoms.

242. The orexin-1 receptor antagonist SB-334867 blocks the effects of antipsychotics on the activity of A9 and A10 dopamine neurons: implications for antipsychotic therapy.

243. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT).

244. Are chemotherapy patients' HRQoL importance weights consistent with linear scoring rules? A stated-choice approach.

245. Stated preferences of patients with cancer for health-related quality-of-life (HRQOL) domains during treatment.

246. Development of the cancer therapy satisfaction questionnaire: item generation and content validity testing.

247. The economic cost of squamous cell cancer of the head and neck: findings from linked SEER-Medicare data.

248. The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons.

249. Reliability and validity of a chronic care facility adaptation of the Clinical Dementia Rating scale.

250. The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement.

Catalog

Books, media, physical & digital resources